Although much of the therapeutic research in LOAD has been geared toward targeting Aβ and tau pathologies, the role of apoE as a common mediator of several amyloid-dependent and amyloid-independent pathways suggests that apoE itself could be a powerful target upstream of multiple AD pathologies. This evidence concerns the gene MAPT and Alzheimer disease.